ST Germain D J Co. Inc. grew its stake in Novo Nordisk A/S (NYSE:NVO) by 7.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 193,874 shares of the company’s stock after purchasing an additional 12,640 shares during the quarter. ST Germain D J Co. Inc.’s holdings in Novo Nordisk A/S were worth $9,895,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. TCG Advisors LP acquired a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $27,000. Camarda Financial Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $28,000. Harvest Group Wealth Management LLC acquired a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $29,000. Valeo Financial Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 510.7% in the 2nd quarter. Valeo Financial Advisors LLC now owns 629 shares of the company’s stock valued at $32,000 after purchasing an additional 526 shares during the period. Finally, WP Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $39,000. 7.12% of the stock is currently owned by institutional investors.
Several analysts recently commented on NVO shares. Pareto Securities downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Deutsche Bank downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price objective on the stock. in a research note on Thursday, June 20th. Barclays raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 price objective on the stock in a research note on Tuesday, June 11th. UBS Group reaffirmed a “buy” rating and set a $355.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, June 19th. Finally, Credit Suisse Group raised Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Monday, April 29th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $111.58.
Novo Nordisk A/S stock traded up $0.15 during mid-day trading on Friday, hitting $48.72. 1,285,362 shares of the company’s stock were exchanged, compared to its average volume of 1,780,926. The firm has a market capitalization of $118.99 billion, a price-to-earnings ratio of 19.33, a P/E/G ratio of 2.23 and a beta of 0.60. Novo Nordisk A/S has a fifty-two week low of $41.23 and a fifty-two week high of $52.83. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 0.07. The company has a 50 day moving average price of $49.84.
Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Friday, May 3rd. The company reported $0.66 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.04. The business had revenue of $4.46 billion for the quarter, compared to the consensus estimate of $4.35 billion. Novo Nordisk A/S had a return on equity of 78.28% and a net margin of 33.60%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 2.43 earnings per share for the current fiscal year.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Further Reading: How to invest in blue-chip stocks
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.